• FDA Roundup US Food and Drug Safety News

  • By: Quiet. Please
  • Podcast

FDA Roundup US Food and Drug Safety News

By: Quiet. Please
  • Summary

  • The latest news and events as reported by the U.S. Food and Drug Administration (FDA)

    Covers news on food and drugs. including recalls and important information about the food we consume and the drugs we take.
    Copyright 2023 Quiet. Please
    Show more Show less
activate_Holiday_promo_in_buybox_DT_T2
Episodes
  • FDA Roundup for 10-27-2023 Food and Drug Safety news
    Oct 31 2023
    This is the FDA Roundup as reported by the United States of America’s Food and Drug Administration on October 27th, 2023.And this is your at-a-glance summary of news from around the agency:Today, the FDA Center for Tobacco Products (CTP) Director Brian King published a statement summarizing the center’s continued efforts to address the operational evaluation of CTP by an independent expert panel facilitated by the Reagan-Udall Foundation (RUF). A comprehensive list of status updates for each recommendation is also available at the updated Actions to Address Recommendations from the Reagan-Udall Evaluation of CTP webpage.On Thursday, the FDA cleared Alltest Fentanyl Urine Test Cassette, the first over the counter test for the preliminary detection of fentanyl in urine. The test works by placing three drops of fresh urine onto a cassette containing a fentanyl test strip. After 5 minutes the test result will appear as colored lines.“Opioid abuse, misuse and addiction is one of the most profound public health crises facing the U.S. today. It is also a very personal issue for many people, impacting individual lives and families,” said Jeff Shuren, M.D., J.D., Director, FDA’s Center for Devices and Radiological Health. “This test is an example of the FDA’s continued commitment to authorize tools that can reduce deaths associated with overdoses. The agency expedited review of this test, making a decision on the submission in only 16 days from the date it was received.”The test provides only preliminary results. A more specific alternative chemical method (confirmation testing) must be used in order to obtain a confirmed test result. The test includes a pre-addressed mailing box for shipping samples to the manufacturer’s laboratory for confirmation testing. The test may provide incorrect results if the urine sample is contaminated, for example by adding bleach. The test does not distinguish between drugs of abuse and certain medications. Certain foods or food supplements may give a false positive test result.On Thursday, the FDA published CDER From Our Perspective: “Updated FDA Labeling Recommendations for Biosimilar and Interchangeable Biosimilar Products” by Sarah Yim, M.D., director of the Office of New Drugs’ Office of Therapeutic Biologics and Biosimilars (OTBB). Dr. Yim speaks to recent recommendations in OTBB draft labeling guidance that reflect experience with labeling considerations for biosimilar and interchangeable biosimilar products (interchangeable biosimilars), noting that the draft guidance recommendations have been revised to specifically include interchangeable biosimilar products. Dr. Yim also explains new recommendations for the “Biosimilarity Statement” in the “prescribing information” of biosimilar and interchangeable biosimilar product labeling.On Thursday, the FDA approved Agamree (Santhera Pharmaceuticals, Inc.) an oral corticosteroid for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. DMD is a rare disorder which causes progressive muscle weakness due to a lack of muscle protein called dystrophin. Males are more commonly affected by the disorder which can be fatal. The most common side effects are cushingoid features (Cushing’s syndrome), psychiatric disorders, vomiting, weight gain and vitamin D deficiency. View the full prescribing information for Agamree. The FDA granted this application orphan drug designation.On Wednesday, the FDA published the FDA Voices: “India’s Unique Opportunity and Important Responsibility as the Pharmacy to the World,” by Robert M. Califf, M.D., Commissioner of Food and Drugs. The FDA Commissioner Robert M. Califf recently traveled to India, visiting the capital city of New Delhi and the pharmaceutical and technology hub Hyderabad. He reflects about that trip in the FDA Voices article.On Wednesday, the FDA issued a draft guidance on Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities, replacing the previously issued guidance, Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities During the COVID-19 Public Health Emergency. The FDA often used voluntary remote interactive evaluations during the COVID-19 pandemic. After their successful use, the FDA is issuing the draft guidance to inform industry about the agency’s continued use of such remote evaluations, as appropriate.On Tuesday, the FDA issued an Outbreak Advisory for an investigation of Salmonella Thompson infections linked to fresh diced onions from Gills Onions of Oxnard, California. In response to this investigation, Gills Onions voluntarily recalled diced yellow onions, diced onions & celery, diced mirepoix, and diced red onions with use-by dates in August 2023. Consumers should not eat, sell, or serve recalled onions and should check their freezers if they froze recalled products. Full descriptions of recalled products sold to retailers in AZ...
    Show more Show less
    7 mins

What listeners say about FDA Roundup US Food and Drug Safety News

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.